Hutchmed (HCM) said late Monday that China's National Medical Products Administration has approved its supplemental new drug application for Orpathys to treat certain adult patients with non-small cell lung cancer.
The drugmaker said the regulator also converted Orpathys' prior conditional approval for previously treated patients to full approval.
The updated label will now include both treatment-naive and previously treated patients in China, Hutchmed said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.